Search results
Showing 1 to 8 of 8 results for mesalazine
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
This is a summary of the most common accessibility changes we are making in guidelines, and why
Show all sections
successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no...
The committee also reviewed theevidence for aminosalicylates (such as mesalazine). The evidence on relapse rates...
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no...
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.